Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
For women with triple-negative breast cancer (TNBC), adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy was more beneficial for those diagnosed with basal-like tumors compared to those with nonbasal-like tumors. This data was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), held Dec. 9-13, 2014.
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.
The level of stromal tumor-infiltrating lymphocytes (Str-TILs) may influence which treatment is the most effective in women with HER2-positive breast cancer.
In this preview of the 2014 San Antonio Breast Cancer Symposium, we take a look at some of the studies to watch for at this year's event.